Research article summary (published 29 Sep 2009):

Tamoxifen, antidepressants, and CYP2D6: the conundrum continues.

Full Abstract

No abstract is available for this article. See 'Journal and Publication Information' further down the page for details that may assist you in locating this article in electronic or hard copy media. The 'Related articles' section also further down the page, where available, may show links to abstracts of articles covering similar topics.

Author information

Author/s: Holzman, David (D);

Journal and publication information

Publication Type: Journal Article

Journal: Journal of the National Cancer Institute (J Natl Cancer Inst), published in United States. (Language: eng)

Reference: 2009-Oct; vol 101 (issue 20) : pp 1370-1

Dates: Created 2009/10/22; Completed 2009/11/02;

PMID: 19797723, status: MEDLINE (last retrieval date: 11/2/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Antidepressive Agents - pharmacology Antineoplastic Agents, Hormonal - pharmacokinetics Aromatase Inhibitors - pharmacology Breast Neoplasms - drug therapy; prevention & control Cytochrome P-450 CYP2D6 - antagonists & inhibitors; genetics Female Humans

Humans Postmenopause Premenopause Recurrence Selective Estrogen Receptor Modulators - pharmacokinetics Serotonin Uptake Inhibitors - pharmacology Tamoxifen - analogs & derivatives; pharmacokinetics; pharmacology

Associated Chemicals: Antidepressive Agents (0) ; Antineoplastic Agents, Hormonal (0) ; Aromatase Inhibitors (0) ; Selective Estrogen Receptor Modulators (0) ; Serotonin Uptake Inhibitors (0) ; Tamoxifen (10540-29-1) ; 4-hydroxy-N-desmethyltamoxifen (110025-28-0) ; Cytochrome P-450 CYP2D6 (EC 1.14.14.1)

Related articles

These are the highest related articles currently in the database:

• Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. 16 Oct 2007
• Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer. 30 Oct 1995
• Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Dec 2003
• Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. 13 Dec 2005
• Tamoxifen pharmacogenetics moves closer to reality. 14 Mar 2005
• A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? 27 Apr 2008
• Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling. 29 Nov 2006
• Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients. 21 Feb 2008
• Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. 30 Aug 2001
• CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. 30 Dec 1999

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.